Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

857 ARTÍCULOS , VIENDO DEL 751 AL 765

Measurement Error and Methodologic Issues in Analyses of the Proportion of Variance Explained in Cognition

Nichols E, Aslanyan V, Adrien TV, Andrews RM, Fardo DW, Gavett BE, Paterson TSE, Turney IC, Young CB, Uanhoro JO, Gross AL, Initiative FTADN.

Neuropsychol Rev. 2025 Dec;35(4):731-744. doi: 10.1007/s11065-024-09655-1. Epub 2024 Nov 20.

Early axonal degeneration linked to clinical decline in Alzheimer's disease progression revealed with diffusion MRI

Gong Z, Laporte JP, Guo AY, Bilgel M, Bae J, Fox NY, de Rouen A, Zhang N, Taranath A, de Cabo R, Egan JM, Ferrucci L, Bouhrara M; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Invest. 2025 Nov 27;136(3):e196638. doi: 10.1172/JCI196638. eCollection 2026 Feb 2.

Evaluation of early-phase (18)F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with (18)F-FDG PET at group and single patient level

Lojo-Ramírez JA, Fernández-Rodríguez P, Guerra-Gómez M, Marín-Cabañas AM, Franco-Macías E, Jiménez-Hoyuela-García JM, García-Solís D.

J Alzheimers Dis. 2025 Jul;106(1):304-316. doi: 10.1177/13872877251340380. Epub 2025 May 8.

The Eye as a Window to Brain Health: Can Retinal Imaging and AI Modeling Predict Alzheimer's Disease?

Awodiya E.

Brain Behav. 2025 Oct;15(10):e70890. doi: 10.1002/brb3.70890.

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, Vanderstichele H, Kaplow J, Dean RA, Stoops E, Vanmechelen E, Koel-Simmelink MJA, Teunissen CE, Sethuraman G, Feaster T, Siemers E, Jerecic J.

J Prev Alzheimers Dis. 2025 Apr;12(4):100082. doi: 10.1016/j.tjpad.2025.100082. Epub 2025 Feb 17.

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

Liou JJ, Lou J, Flores-Aguilar L, Nakagiri J, Yong W, Hom CL, Doran EW, Totoiu MO, Lott I, Mapstone M, Keator DB, Brickman AM, Wright ST, Nelson B, Lai F, Xicota L, Dang LT, Li J, Santini T, Mettenburg JM, Ikonomovic MD, Kofler J, Ibrahim T, Head E; Alzheimer Biomarker Consortium ‐ Down Syndrome.

Alzheimers Dement. 2025 Feb;21(2):e14479. doi: 10.1002/alz.14479. Epub 2025 Jan 27.

Brain health clinics - An evolving clinical pathway?

Butters AF, Blackman J, Farouk H, Meky S, A Newson M, Lemke T, Rosewell N, Selwood JA, Turner NL, Coulthard EJ, Archer HA.

J Prev Alzheimers Dis. 2025 Mar;12(3):100051. doi: 10.1016/j.tjpad.2024.100051. Epub 2025 Feb 3.

Alternative TMA-93 version demonstrates comparable performance and discriminative accuracy in early Alzheimer's disease

Arriola-Infante JE, García-Roldán E, García-Solís D, Lojo-Ramírez JA, Marín-Cabañas AM, Luque-Tirado A, Almodóvar-Sierra Á, Bernal Sánchez-Arjona M, Maillet D, Franco-Macías E.

J Alzheimers Dis. 2025 Dec;108(3):1347-1356. doi: 10.1177/13872877251386479. Epub 2025 Oct 16.

Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease

Zeydan B, Kantarci K.

Rev Neurol (Paris). 2025 Nov;181(9):829-838. doi: 10.1016/j.neurol.2025.06.015. Epub 2025 Aug 6.

Comparison of CSF neurofilament light chain and total tau as neurodegeneration markers: Associations with synaptic markers and cognitive outcomes

Richter G, Kirsebom BE, Jarholm JA, Pålhaugen L, Gísladóttir B, Aarsland D, Grøntvedt GR, Skogseth RE, Waterloo K, Fladby T, Nordengen K.

Neurobiol Aging. 2025 Nov;155:13-23. doi: 10.1016/j.neurobiolaging.2025.07.005. Epub 2025 Jul 10.

Association between Serum Levels of Interleukin-6 and Stroke, Cardiovascular Events, and Alzheimer's Disease Dementia

Kitagawa K, Toi S, Yoshizawa H, Sato Y, Todo K.

J Atheroscler Thromb. 2025 Nov 1;32(11):1390-1399. doi: 10.5551/jat.65763. Epub 2025 Jun 6.

Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment

Alvarez-Sanchez L, Pereto M, Garcia-Valles L, Balaguer A, Pena-Bautista C, Ferre-Gonzalez L, Baquero M, Pericas CC.

Curr Neuropharmacol. 2025;23(5):602-611. doi: 10.2174/011570159X332930240925095423.

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

Guillén N, Contador J, Buongiorno M, Álvarez I, Culell N, Alcolea D, Lleó A, Fortea J, Piñol-Ripoll G, Carnes-Vendrell A, Lourdes Ispierto M, Vilas D, Puig-Pijoan A, Fernández-Lebrero A, Balasa M, Sánchez-Valle R, Lladó A.

Eur Arch Psychiatry Clin Neurosci. 2025 Feb;275(1):257-266. doi: 10.1007/s00406-023-01701-y. Epub 2023 Oct 28.

Brain outcomes with lifestyle change in adults with Down syndrome: Rationale and design for a 12-month randomized trial

Ptomey LT, Donnelly JE, Burns J, Morris J, Hartley S, Martin LE, Choi IY, Lee P, Li Y, Hunt S, Sherman JR, Danon JC, Brucks MG, Koon L, Spaeth K, Sullivan DK.

Alzheimers Dement. 2025 Apr;21(4):e70219. doi: 10.1002/alz.70219.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias